Abstract

ARUS SOLER, Enrique et al. Tratamiento de la hepatitis viral aguda c con interferón alfa 2b recombinante: Ensayo clínico. Rev cubana med [online]. 2000, vol.39, n.1, pp. 21-29. ISSN 1561-302X.

A clinical trial was carried out aimed at evaluating the efficacy and safety of interferon in a group of 13 patients with acute hepatitis C. The diagnosis was made according to biochemical criteria (alanine aminotransferase 2 ti-mes the normal value), serological criteria (presence of anti-hepatitis C virus antibodies) and histological criteria. Treatment with recombinant interferon alfa 2b 3 000 000 IU/ml inj. was indicated 3 times a week during 13 weeks. It was proved that 53.8 % finished the period of treatment with normal alanine aminotransferase and that at the end of the follow-up 30.7 % had a mantained biochemical response. 4 patients (36.3 %) of the 11 that concluded the follow-up had a normal histology in the evolutive hepatic biopsy and of them 2 had a mantained biochemical response, which made us think they were cured. Interferon was well tolerated and only 38.5 % of the patients showed secondary manifestations of toxicity. It was observed a predominance of cephalalgia, fever, myalgias and arthralgias. It was concluded that interferon should be used in patients with acute hepatitis C in extension protocols that will allow the generalization of this treatment in the future.

Keywords : HEPATITIS C, CHRONIC; INTERFERONS [drug therapy.].

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )